CDMO has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
CDMO has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Avid Bioservices's average Accounts Receivable for the three months ended in Oct. 2023 was $14.8 Mil. Avid Bioservices's Revenue for the three months ended in Oct. 2023 was $25.4 Mil. Hence, Avid Bioservices's Days Sales Outstanding for the three months ended in Oct. 2023 was 53.16.
The historical rank and industry rank for Avid Bioservices's Days Sales Outstanding or its related term are showing as below:
During the past 13 years, Avid Bioservices's highest Days Sales Outstanding was 60.11. The lowest was 23.31. And the median was 36.98.
Avid Bioservices's Days Sales Outstanding declined from Oct. 2022 (61.07) to Oct. 2023 (53.16).
The historical data trend for Avid Bioservices's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Avid Bioservices Annual Data | |||||||||||||||||||||
Trend | Apr14 | Apr15 | Apr16 | Apr17 | Apr18 | Apr19 | Apr20 | Apr21 | Apr22 | Apr23 | |||||||||||
Days Sales Outstanding | Get a 7-Day Free Trial | 37.16 | 48.85 | 52.25 | 60.11 | 47.49 |
Avid Bioservices Quarterly Data | ||||||||||||||||||||
Jan19 | Apr19 | Jul19 | Oct19 | Jan20 | Apr20 | Jul20 | Oct20 | Jan21 | Apr21 | Jul21 | Oct21 | Jan22 | Apr22 | Jul22 | Oct22 | Jan23 | Apr23 | Jul23 | Oct23 | |
Days Sales Outstanding | Get a 7-Day Free Trial | 61.07 | 42.49 | 37.97 | 41.73 | 53.16 |
For the Biotechnology subindustry, Avid Bioservices's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Avid Bioservices's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Avid Bioservices's Days Sales Outstanding falls into.
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
Accounts Receivable can be measured by Days Sales Outstanding.
Avid Bioservices's Days Sales Outstanding for the fiscal year that ended in Apr. 2023 is calculated as
Days Sales Outstanding (A: Apr. 2023 ) | |||||||||
= | Average Accounts Receivable | / | Revenue | * | Days in Period | ||||
= | ( (Accounts Receivable (A: Apr. 2022 ) | + | Accounts Receivable (A: Apr. 2023 )) | / | count ) | / | Revenue (A: Apr. 2023 ) | * | Days in Period |
= | ( (20.547 | + | 18.298) | / | 2 ) | / | 149.266 | * | 365 |
= | 19.4225 | / | 149.266 | * | 365 | ||||
= | 47.49 |
Avid Bioservices's Days Sales Outstanding for the quarter that ended in Oct. 2023 is calculated as:
Days Sales Outstanding (Q: Oct. 2023 ) | |||||||||
= | Average Accounts Receivable | / | Revenue | * | Days in Period | ||||
= | ( (Accounts Receivable (A: Jul. 2023 ) | + | Accounts Receivable (A: Oct. 2023 )) | / | count ) | / | Revenue (A: Oct. 2023 ) | * | Days in Period |
= | ( (16.209 | + | 13.379) | / | 2 ) | / | 25.395 | * | 365 / 4 |
= | 14.794 | / | 25.395 | * | 365 / 4 | ||||
= | 53.16 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Avid Bioservices (NAS:CDMO) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Thank you for viewing the detailed overview of Avid Bioservices's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.
Matthew R. Kwietniak | officer: Chief Commercial Officer | 14191 MYFORD ROAD, TUSTIN CA 92780 |
Richard A. Richieri | officer: Chief Operations Officer | 14191 MYFORD ROAD, TUSTIN CA 92780 |
Daniel Ryan Hart | officer: Chief Financial Officer | 2642 MICHELLE DR., SUITE 200, TUSTIN CA 62780 |
Mark R Ziebell | officer: V.P., General Counsel | 14282 FRANKLIN AVENUE, TUSTIN CA 92780 |
Richard B Hancock | director | 14282 FRANKLIN AVE., TUSTIN CA 92780 |
Joseph Carleone | director | 3883 HOWARD HUGHES PKWY, SUITE 700, LAS VEGAS NV 89169 |
Nicholas Stewart Green | director, officer: President & CEO | 2642 MICHELLE DRIVE, SUITE 200, TUSTIN CA 92780 |
Gregory Sargen | director | |
Esther M. Alegria | director | 2642 MICHELLE DRIVE, SUITE 200, TUSTIN CA 92780 |
Mark R Bamforth | director | 500 KENDALL ST., CAMBRIDGE MA 02142 |
Jeanne Thoma | director | C/O ANI PHARMACEUTICALS, INC., 210 MAIN STREET WEST, BAUDETTE MN 56623 |
Patrick D Walsh | director | 14282 FRANKLIN AVE., TUSTIN CA 92780 |
Catherine J Mackey | director | 3595 JOHN HOPKINS COURT, SAN DIEGO CA 92121 |
Joel Mccomb | director | 9885 TOWNE CENTRE DRIVE, SAN DIEGO CA 92121 |
Stephen Michael Hedberg | officer: Principal Fin. & Acct. Officer | 2642 MICHELLE DRIVE, SUITE 200, TUSTIN CA 92780 |
From GuruFocus
By Marketwired • 10-17-2023
By GuruFocus Research • 12-19-2023
By Marketwired • 09-26-2023
By PRNewswire PRNewswire • 07-06-2022
By PRNewswire PRNewswire • 06-16-2022
By GuruFocusNews GuruFocusNews • 06-22-2022
By Ds*** Ds*** • 08-30-2022
By Marketwired • 06-21-2023
By GuruFocusNews GuruFocusNews • 07-04-2022
By PurpleRose PurpleRose • 07-12-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.